Cytek Biosciences Reports Third Quarter 2026 Financial Results
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Cytek (CTKB) Q3 revenue $53.2 million, up 2% year over year
- ➤GAAP gross margin 59%, up 590 basis points year over year
- ➤2026 revenue guidance maintained midpoint, narrowed to $208 million to $211 million
- ➤Trailing-12-month recurring revenue mix reached 36%, up from 33%
- ➤Jury found Cytek non-infringing or claims invalid on three of four claims
Expert Statements
Wenbin Jiang, CEO of Cytek Biosciences
“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business. Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”
FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026.
Recent Highlights * Total revenue for the third quarter of 2026 was $53.2 million, representing a 2% increase compared to the third quarter of 2025
Get started
Create a free account to read the full story.